Drug Combination Details
| General Information of the Combination (ID: C12224) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Etoposide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of resveratrol and etoposide showed synergistic anti-proliferative effect on hepatocellular carcinoma cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic anti-proliferative effect of resveratrol and etoposide on human hepatocellular and colon cancer cell lines. Eur J Pharmacol. 2013 Oct 15;718(1-3):34-40. | |||
